We compared daily T 4 therapy with 7 times the normal daily dose administered once weekly in 12 hypothyroid subjects in a randomized cross-over trial. At the end of each treatment we measured serum free T 4 (FT 4 ), free T 3 (FT 3 ), rT 3 , and TSH levels and multiple markers of thyroid hormone effects at the tissue level repeatedly for 24 h.
T 4 REPLACEMENT for hypothyroidism usually achieves complete restoration of euthyroidism. However, daily, lifelong administration can lead to patient noncompliance. T 4 has an elimination half-life of about 7 days (1, 2), but its biological effect may be longer. It is a prohormone, the active hormone is T 3 (3, 4) , formed from T 4 in peripheral tissues. There is strong evidence for autoregulation of the peripheral conversion of T 4 to T 3 , with increasing conversion rates at low serum T 4 levels and decreasing conversion when serum T 4 is elevated (5) (6) (7) (8) . Together, these properties suggest the possibility of using a dosing interval longer than the traditional 24 h. Weekly dosing may improve compliance in some patients and could be advantageous to nurses or other caregivers when T 4 must be administered to patients unable to dose themselves.
During the 1960s through early 1980s, studies demonstrated that single doses of T 4 up to 3 mg are well tolerated (9 -13) . However, peripheral thyroid hormone measurements were largely limited to total serum T 4 and T 3 (11) (12) (13) , although one study included radioactive iodide uptake, protein-bound iodine, T 3 -resin uptake, and free T 4 (FT 4 ) in some patients (9) . Sensitive TSH assays were not available, but two studies measured TRH-stimulated TSH responses (12, 13) . No study measured free T 3 (FT 3 ). Although all studies commented to some degree on patient symptomatology, and one study measured total serum cholesterol (9) , none assessed patient symptoms and thyroid hormone effects at the tissue level in a systematic or comprehensive fashion.
We, therefore, believed that the neither efficacy or safety of once weekly T 4 therapy was established and decided to determine this using current thyroid function tests and measurements of the tissue effects of thyroid hormone. The aim of the study was to determine whether 7 times the daily dose of T 4 administered once weekly was as safe and efficacious as the usual daily dose for maintenance therapy in hypothyroid subjects.
Experimental Subjects
The study protocol and all procedures were approved and monitored by the Capital Coast Health Ethics Committee (Wellington, New Zealand). All patients gave their informed consent.
Statistical power analysis
We used a randomized cross-over design for our study, thus achieving at least 4 times the statistical power of a comparably sized group comparative trial. We estimated that we needed 12 or more patients to achieve 80% power at the 0.05 significance level for detecting differences between daily and weekly treatment of 10 -60% in the mean values of the tests performed. In addition, we ensured that the sample size was sufficient to detect a 10% difference in mean corrected systolic time intervals between the two treatments.
Patients
Fourteen patients were initially enrolled, and 12 subjects completed the study; 1 subject did not commence the study, and another patient developed chest pain of uncertain origin while receiving her normal daily T 4 therapy and was withdrawn before entry into the weekly treatment phase.
Two subjects were male, and 10 were female. The mean age of the study subjects was 50.8 (sd ϭ 14.5) yr. All subjects suffered from confirmed primary hypothyroidism, as evidenced by a clearly elevated serum TSH at the time of diagnosis (Ն20 IU/mL) and at least 1 unsuccessful trial of T 4 withdrawal thereafter. At the time of enrollment all had been receiving T 4 replacement therapy at a stable dose for the least 3 months.
The mean daily T 4 dose was 1.6 g (sd ϭ 0.35 g)/kg BW. At the time of their original diagnoses, all patients had received standard instructions regarding T 4 administration, including taking T 4 separate from other medications and food.
The causes of hypothyroidism were autoimmune thyroiditis in five patients, radioiodine ablation in three patients, subtotal thyroidectomy in two patients, and undetermined in two patients. No patient suffered from severe medical illness, pituitary disease, untreated metabolic bone disease or osteoporosis, liver disease, cardiac disease, or known abnormalities of thyroid hormone metabolism and thyroid hormone protein binding or was taking medications known to interfere with thyroid function or thyroid hormone measurement.
Materials and Methods

Study design
At trial entry, subjects were randomly assigned either to continue with their usual daily maintenance dose of T 4 or to take 7 times the usual daily dose once weekly, beginning on day 1 of the trial. Figure 1 summarizes the trial design. Three patients receiving other medications in addition to T 4 continued to take these in the usual manner and dose during the duration of the trial, and all patients were instructed not to change their normal daily habits (including diet and exercise) during the trial period.
To achieve steady state serum thyroid hormone levels before testing,
FIG.
1. This figure depicts the cross-over trial design and testing schedule used in our study. The upper part of the figure schematically shows the trial design in relation to the relevant time line (in days). At trial entry, 12 hypothyroid subjects receiving stable T 4 replacement were randomized to initially either continue with their normal daily T 4 dose (n ϭ 7) or to start taking 7 times their regular daily dose once per week (n ϭ 5). On days 43/44 and 85/86, all subjects underwent repeated measurements of serum thyroid hormone levels and tissue markers of thyroid hormone effects. The testing schedule is summarized in the table inset at the bottom of the figure. The treatment cross-over occurred after the day 43/44 testing, as detailed in the footnotes to the main part of the figure.
all study subjects continued with their assigned T 4 treatment regimen for 6 weeks, about 6 times the elimination half-life of T 4 . On the 43rd and 44th trial days, all subjects underwent clinical, biochemical, and biophysical tests. The patients taking a daily dose then took 6 times their normal daily dose on day 44 and omitted daily T 4 for the next 6 days. One week after testing (day 50) they then began taking 7 times their daily dose once each week for 5 weeks. Those subjects previously on the weekly dose returned to their daily dose 1 week after testing (day 50) and continued on the daily dose for the next 5 weeks. Testing was repeated on the 85th and 86th trial days. On the days of testing patients attended the Department of Endocrinology, Wellington Hospital, between 0800 -0900 h fasting. On arrival they underwent baseline testing (0 h), which comprised a standardized questionnaire concerning thyroid-related symptoms during the previous week, self-assessment of well-being during the previous week using a visual analog scale, echocardiographic measurement of systolic time intervals, blood sampling for serum thyroid function tests, and measurement of a variety of serum analytes used as tissue markers of thyroid hormone effects. Depending on the treatment period, the subjects then took either their daily or weekly dose of T 4 . Further blood samples were taken after 1, 2, 4, 8, and 24 h. Patients were permitted to eat after the 4-h testing. At 8 h, the echocardiogram was repeated. Patients receiving weekly treatment underwent an additional echocardiogram at 24 h (the 24 h echocardiogram was omitted in patients receiving daily treatment, because it was assumed to be equivalent to the baseline). The questionnaire and self-rated scale of well-being were readministered to all subjects at 24 h. All testing at 24 h was performed after an overnight fast and, for the patients receiving daily treatment, before T 4 was taken.
Details of the testing procedures are summarized in Fig. 1 . The details of the symptom questionnaire are given in Table 1 . For self-assessment of well-being, a previously validated visual analog scale was used (14) . On this scale patients rated their well-being over the preceding week or 24 h on a 100-mm line, with the left end corresponding to "worst ever" (0 mm) and the right end to "best ever" (100 mm).
Immediately after venipuncture and centrifugation, the serum was separated and stored at Ϫ20 C. At the conclusion of the study, all samples for each patient were measured in the same assay to minimize interassay variation.
Serum assays
Thyroid function tests consisted of serum FT 4 , FT 3 , TSH (all measured on the Corning ACS-180ϩ automated immunoanalyzer, Scianz Corp., Auckland, New Zealand), rT 3 (measured by RIA, Biodata, Milan, Italy), and serum T 4 -binding globulin [TBG; using an immunoradiometric assay (IRMA), Corning Medical, Midland, MI]. The functional sensitivity of the TSH assay is 0.03 IU/mL.
As general indicators of thyroid hormone effects at the tissue level, the following, previously validated, parameters (15) (16) (17) were used: sex hormone-binding globulin (by IRMA, Orion Diagnostics, Finland); total cholesterol, high density lipoprotein (HDL), and triglycerides (Hitachi 717 multianalyzer, Boehringer Mannheim, Auckland, New Zealand); and apolipoprotein a (APOa; immunoturbidimetric method, Hitachi 717). Low density lipoprotein (LDL) was calculated from HDL cholesterol and triglyceride concentrations.
To monitor the effects of thyroid hormone on the liver (17-21), aspartate aminotransferase, alanine aminotransferase, and ␥-glutamyltransferase were measured with a Hitachi 717 multianalyzer.
Serum osteocalcin and alkaline phosphatase were used as markers of the influence of thyroid hormones on bone turnover (22) (23) (24) and were measured with an IRMA (Nichols Institute, San Juan Capistrano, CA) and a Hitachi 717 multianalyzer, respectively.
Echocardiography
The cardiac effects of thyroid hormone were estimated by systolic time intervals (STI) measurements, a sensitive marker of these effects (15, (25) (26) (27) (28) (29) (30) . A two-dimensional echocardiogram was performed first, to exclude cardiac conditions known to interfere with STI measurements. The STI were obtained after the two-dimensional study and 15 min of rest by the method described by Tseng et al. (26) , using a dual M-mode system (HP 77020AC Rev F, Hewlett-Packard, Palo Alto, CA) with a chart speed of 100 mm/s. Data were corrected for heart rate and gender (31) , and a total of 10 cycles were analyzed to minimize variation due to respiration.
Data analysis
Data for TSH, FT 4 , and rT 3 followed a log-normal distribution and were log transformed before analysis. Other noncategorical data did not need to be transformed before analysis. Statistical analysis of all data, except for the results of the symptom questionnaire, was performed using multivariate regression and ANOVA for repeated measures (32), with terms for treatment type (weekly vs. daily), treatment sequence (weekly or daily treatment first), and interactions. The GreenhouseGeisser adjustment to degrees of freedom was used to account for the repeated measures on individuals (33) . In addition, the untransformed TSH, FT 4 , and rT 3 data were analyzed using nonparametric equivalents of the parametric statistical tests (Friedman test). The results of the symptom questionnaire were analyzed using McNemar's test, comparing daily with weekly treatment (32) . For all statistical tests, P Ͻ 0.05 was considered significant.
Results
Symptoms
All patients tolerated weekly T 4 treatment well. There were no significant differences at either 0 or 24 h between daily and weekly treatments in the results of the questionnaire and self-rated visual analog scale (Table 1) .
Thyroid function tests
Serum thyroid hormone levels differed between weekly and daily treatment at several time points (Fig. 2) . At 0 h, the mean values for FT 3 (daily, 242; weekly, 208 pg/dL; P Ͻ 0.01), rT 3 (daily, 26.75; weekly, 22 ng/dL; P Ͻ 0.01), and FT 4 (daily, 1.35; weekly, 0.98 ng/dL; P Ͻ 0.001) were significantly lower for the group receiving weekly therapy. For this group, FT 4 was significantly higher at all other time points (all P Ͻ 0.005), peaking at 2 h with both daily and weekly T 4 (daily, 4 . This delay was more pronounced with weekly T 4 . Serum TSH levels with weekly therapy were significantly higher than those with daily treatment at all time points (all P Ͻ 0.04), except 24 h (P ϭ NS). The largest difference occurred at 0 h, with a mean serum TSH value of 3.92 IU/mL with daily T 4 vs. 6.61 IU/mL with weekly T 4 . Serum TSH levels with weekly T 4 fell rapidly in the first hour after T 4 administration and then gradually declined to levels similar to those with daily treatment. Serum TBG results were subject to a treatment sequence effect, with measurements during weekly treatment significantly higher in patients who took daily T 4 first than in those receiving initial weekly treatment. We, therefore, only compared measurements during the first treatment cycle with either daily (n ϭ 7) or weekly (n ϭ 5) therapy. In this comparison the two treatment regimens did not differ significantly. Mean TBG values were between 1.99 -2.04 mg/dL with daily and between 1.92-2.17 mg/dL with weekly treatment.
Markers of tissue effect
There were no significant differences at any time point between daily and weekly treatment in the levels of serum sex hormone-binding globulin, ␥-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase, osteocalcin, alkaline phoshatase (all in Table 2 ), HDL, and LDL (data not shown), but total serum cholesterol differed significantly at 0 h (P Ͻ 0.03), with the mean being 14.2 mg/dL higher during weekly therapy (Table 2) . No difference was found for serum total cholesterol measurements at other times. APOa was subject to a sequence effect. Consequently, as with serum TBG measurements, only the first treatment cycle was used for analysis. No differences between groups were found in serum APOa measurements.
STI measurements did not significantly differ between daily and weekly treatments ( Table 2 ).
Discussion
Our results suggest that once weekly T 4 replacement therapy for hypothyroidism is safe and arguably efficacious, making it a possible alternative to customary daily therapy. Once weekly T 4 replacement was well tolerated, and there was no indication of acute treatment toxicity compared with daily therapy. Although serum FT 4 levels rose significantly after treatment, changes in FT 3 with once weekly therapy were slight, confirming previous studies (9, 11, 13) . However, thyroid function tests demonstrated mild hypothyroidism before weekly treatment, with higher mean serum TSH and lower mean serum FT 4 and FT 3 values. For complete biochemical euthyroidism, a slightly larger dose than 7 times the normal daily dose may be required.
At the peripheral tissue level, the effect of weekly T 4 treatment did not differ from that of customary daily treatment despite differences in serum thyroid hormone levels. The only tissue marker of thyroid hormone effect to suggest hypothyroidism was total serum cholesterol at 0 h. This may have been due to statistical fluctuation. Furthermore, the observed rise was small and seemed to be caused by a rise in both HDL and LDL. It is generally believed that increased serum HDL levels may partially compensate for elevations in LDL (34) . Hence, any potential adverse effect of the small rise in total serum cholesterol may have been mitigated.
One of the mechanisms maintaining near euthyroidism at the tissue level might be a change in the conversion rate of T 4 to T 3 (5, 6) . Whereas serum FT 4 levels almost tripled after the ingestion of weekly T 4 , FT 3 rose by about 25%, and rT 3 rose by about 50%, suggesting preferential conversion of T 4 to the metabolically inactive rT 3 . By contrast, at the end of the dosing interval, FT 4 levels during weekly treatment were almost 30% lower than those during daily treatment, whereas FT 3 levels were 15% lower, and rT 3 levels were 18% lower. This indicates that at the end of weekly treatment, conversion of T 4 to T 3 increased, and conversion to rT 3 decreased.
It could be argued that the tests of peripheral thyroid hormone effect employed were too insensitive and the number of subjects studied too small to detect subtle changes in the thyroid state. However, even in subclinical thyroid states most of the tests used are discriminatory (15-17, 20, 23-26, 35) . STI are shortened in patients with subclinical hyperthyroidism (25, 26) and lengthened in subclinical hypothyroidism (15, 26) . All the changes observed are around 20% and within the range of the power of our study. The response of STI to changes in serum thyroid hormone levels is rapid, showing significant differences in less than 2 weeks after the onset of hypothyroidism (28, 29) .
However, continuous 24-h electrocardiogram monitoring, which generally parallels echocardiographic measurements of cardiac status (36), was not performed, and therefore, we cannot exclude the possibility of asymptomatic cardiac arrhythmia as a result of weekly T 4 treatment. In addition, the absence of data on thyroid function tests and tissue markers during days 2-6 after weekly treatment in our study could underestimate the toxicity of weekly treatment. According to some studies, peak conversion of T 4 to T 3 may not occur until 2-4 days after the ingestion of large T 4 doses (37, 38) , although the rise after 24 h is slight if free T 3 is measured (37) . However, other studies have suggested that T 4 doses between 2.4 -300 mg will lead to a T 3 peak before 24 h (11, 39) . Our data suggest that FT 3 levels plateau at around 4 h (and are in the lower third of the reference range), but we did not observe a fall in mean FT 3 at 24 h. Consequently, we cannot completely dismiss the possibility of toxicity between days 2-6 after weekly treatment. However, in a pilot project involving two subjects (not included in this study) sampled at 0, 1, 2, 4, 8, 24, and 72 h, FT 3 values at 72 h were between peak (24 h) and nadir (0 h) values.
As we do not have firm safety data for the period between 2 and 6 days after T 4 administration or any direct assessment of potentially harmful arrhythmias, we would be hesitant to use weekly T 4 treatment in individuals with ischemic heart disease who may be sensitive to T 4 (18) . We also do not know whether weekly T 4 may be suitable to suppress TSH secretion, although our data suggest that the T 4 dose will have to be increased significantly above 7 times the normal daily dose to ensure suppression over a week. An increase in the weekly dose above 7 times the patient's usual daily dose might be possible without undue risk, but further study is needed on its effects on the skeletal system (22-24) and heart (36). Finally, in some patients weekly treatment could also be hazardous if several doses are missed. Clinicians and patient must work out a schedule that minimizes such risks before switching to weekly T 4 therapy.
